Bedrijfsoverzicht
Arrowhead Pharmaceuticals, Inc. is a biotechnology enterprise dedicated to the development of therapeutic medicines designed to treat intractable diseases within the United States. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on advanced research and development to bring novel molecular entities to market. Currently, the firm employs a workforce of 711 individuals and maintains a substantial market capitalization of $9.12 billion. In the trailing twelve months, the company reported a total revenue of $1.09 billion, figures that collectively position Arrowhead as a significant player with a large valuation relative to its operational scale. This market capitalization suggests that the market assigns a high premium to the company's future potential and existing asset base, while the revenue volume indicates a robust commercial footprint that supports its extensive pipeline of clinical trials.
Financiële gezondheid
In the trailing twelve months, Arrowhead generated a net income of $202.26 million from a revenue base of $1.09 billion, resulting in an EBITDA of $325.65 million. The substantial gap between the reported revenue and the net income reveals a cost structure where operating expenses, while high, are effectively managed to generate significant profitability before interest and taxes. The company reported free cash flow of $170.73 million, a metric that demonstrates strong financial flexibility allowing for continued investment in clinical programs without immediate need for external capital raising. The margin profile is characterized by a gross margin of 100.0%, indicating that the cost of goods sold is negligible relative to sales, which is typical for biotechnology products, while the operating margin stands at 15.5% and the profit margin reaches 18.5%. Regarding leverage, the company holds $914.71 million in cash against $698.16 million in debt, supported by a debt-to-equity ratio of 124.07, which presents a leveraged balance sheet structure typical for growth-stage biotech firms. Liquidity is further evidenced by a current ratio of 3.38, signaling a highly conservative short-term position where current assets significantly exceed current liabilities. Finally, the return on equity is an impressive 75.5% and the return on assets is 14.4%, metrics that reveal highly effective management in generating returns on the capital invested in the business.
Waarderingsbeoordeling
The valuation metrics present a trailing P/E ratio of 40.71 and a forward P/E of -15.16, where the divergence between these figures implies that the market expects earnings to turn negative or contract in the immediate future based on analyst projections. The price-to-book ratio is 15.75, which indicates that the stock trades at a significant market premium over its tangible book value, reflecting high growth expectations rather than current asset backing. Alternative valuation measures include a price-to-sales ratio of 8.36 and an EV/EBITDA of 27.33, suggesting that the market values the company primarily on its sales growth and enterprise value efficiency rather than traditional earnings multiples. The stock has exhibited significant volatility, trading between a 52-week high of $76.76 and a 52-week low of $10.92. Without a specific current share price provided in the source data, the position relative to the range cannot be calculated as a percentage, but the range itself highlights the extreme variance experienced by the security over the past year. The beta value is 1.27, indicating that the share price is more volatile than the broader market, moving 27% more than the market index on average during periods of fluctuation.
Growth & Income
Revenue growth for the trailing twelve months was recorded at 10461.3%, reflecting a massive expansion in sales figures compared to the prior year, whereas earnings growth is listed as N/A due to the specific reporting period or data availability constraints. The discrepancy where revenue growth is quantified while earnings growth is unavailable suggests that the primary driver of value creation is top-line expansion rather than immediate earnings acceleration. Arrowhead does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all of its earnings directly back into research, development, and clinical trial activities to fuel long-term growth. Consequently, the overall growth and income profile is defined by aggressive reinvestment of capital and high revenue expansion, rather than providing current income to shareholders through dividend distributions.